Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue
19 mai 2021 02h30 HE
|
Allarity Therapeutics A/S
- Proceeds will finance further development of three high-priority programs - More than SEK 100 million covered by subscription undertakings and guarantee commitments Press release Hørsholm,...
Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue
05 mai 2021 17h11 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (5 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced an update of the preliminary timetable for the planned Rights Issue announced on...
Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress
29 avr. 2021 10h31 HE
|
Allarity Therapeutics A/S
- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...
MINUTES OF ANNUAL GENERAL MEETING 2021
15 avr. 2021 15h00 HE
|
Allarity Therapeutics A/S
On 15 April 2021 at 15:00 (CEST), the annual general meeting (the "General Meeting") of Allarity Therapeutics A/S, company registration (CVR) no. 28 10 63 51 (the "Company"), was held at c/o...
Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib
02 avr. 2021 07h00 HE
|
Allarity Therapeutics A/S
- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Press release ...
Notice of Annual General Meeting
31 mars 2021 17h00 HE
|
Allarity Therapeutics A/S
31 March 2021 ALLARITY THERAPEUTICS A/S THURSDAY 15 APRIL 2021 AT 15:00 (CEST) The board of directors hereby convenes the Annual General Meeting of Allarity Therapeutics A/S, company...
Allarity Therapeutics Publishes its Annual Report for 2020
31 mars 2021 02h30 HE
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (31 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the issuance of its Annual Report for 2020. The report is available as an...
Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million
23 mars 2021 03h30 HE
|
Allarity Therapeutics A/S
- Proceeds will finance further development of three high-priority programs- Rights Issue is fully covered by subscription undertakings and guarantee commitments - The Company will discontinue the use...
Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
09 mars 2021 07h00 HE
|
Allarity Therapeutics A/S
- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release Hørsholm, Denmark (9 March 2021) – Allarity...
Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer
04 mars 2021 09h00 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2...